Bristol-Myers Squibb (BMY) Q2 2025 Earnings
Bristol-Myers Squibb reported Q2 2025 revenue of $12.3B (+0.6% YoY), beat analyst consensus of $11.4B by $824.8M. Diluted EPS came in at $1.46 (-29.5% YoY), beat the $1.09 consensus by $0.37. Bristol-Myers Squibb reports across 1 business segment, led by Biopharmaceuticals.
Financial Snapshot
Trailing eight quarters through Q2 2025
Q2 2025 Earnings FAQ
Common questions about Bristol-Myers Squibb's Q2 2025 earnings report.
Bristol-Myers Squibb (BMY) reported Q2 2025 earnings on July 31, 2025 before market open.
Bristol-Myers Squibb reported revenue of $12.3B and diluted EPS of $1.46 for Q2 2025.
Revenue beat the consensus estimate of $11.4B by $824.8M. EPS beat the consensus estimate of $1.09 by $0.37.
Compared to the same quarter a year prior, revenue grew 0.6% from $12.2B a year earlier and diluted EPS declined 29.5% from $2.07.
You can read the 10-Q periodic report (0000014272-25-000131) directly on SEC EDGAR. The filing index links above go to sec.gov.